These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38776431)

  • 21. First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: A United States-based cost-effectiveness analysis.
    Wan X; Luo X; Tan C; Zeng X; Zhang Y; Peng L
    Cancer; 2019 Oct; 125(20):3526-3534. PubMed ID: 31287562
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost‑effectiveness analysis of tislelizumab plus chemotherapy in Chinese patients with advanced or metastatic oesophageal squamous cell carcinoma.
    Zhang L; Su H; Liang X; Chen X; Li Y
    Sci Rep; 2024 Jul; 14(1):17734. PubMed ID: 39085374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer.
    Ding D; Hu H; Liao M; Shi Y; She L; Yao L; Zhu Y; Zeng S; Huang J
    Adv Ther; 2020 May; 37(5):2116-2126. PubMed ID: 32193809
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness analysis of atezolizumab plus bevacizumab versus sorafenib in first line treatment for Chinese subpopulation with unresectable hepatocellular carcinoma.
    Tseng CY; Tsai YW; Shiu MN
    Front Oncol; 2023; 13():1264417. PubMed ID: 38023232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness analysis of continuing bevacizumab plus chemotherapy versus chemotherapy alone after first progression of metastatic colorectal cancer.
    Li Y; Hu M; Zhang Z; Chu M; Xu R; Liu L; Dong W; Yang M; Zhang R
    Cancer Med; 2024 Jan; 13(1):e6904. PubMed ID: 38186268
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estimated Cost-effectiveness of Atezolizumab Plus Cobimetinib and Vemurafenib for Treatment of BRAF V600 Variation Metastatic Melanoma.
    Cai C; Yunusa I; Tarhini A
    JAMA Netw Open; 2021 Nov; 4(11):e2132262. PubMed ID: 34762112
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
    Zhang P; Yang Y; Wen F; Wheeler J; Fu P; Li Q
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1978-1985. PubMed ID: 27118432
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-Effectiveness of Atezolizumab Plus Chemotherapy as First-Line Therapy for Metastatic Urothelial Cancer.
    Qin S; Yi L; Li S; Tan C; Zeng X; Wang L; Peng Y; Wan X
    Adv Ther; 2021 Jun; 38(6):3399-3408. PubMed ID: 34019245
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.
    Cheng AL; Qin S; Ikeda M; Galle PR; Ducreux M; Kim TY; Lim HY; Kudo M; Breder V; Merle P; Kaseb AO; Li D; Verret W; Ma N; Nicholas A; Wang Y; Li L; Zhu AX; Finn RS
    J Hepatol; 2022 Apr; 76(4):862-873. PubMed ID: 34902530
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First-line systemic treatment strategies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis.
    Wang L; Peng Y; Qin S; Wan X; Zeng X; Li S; Liu Q; Tan C
    PLoS One; 2023; 18(4):e0279786. PubMed ID: 37053300
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-Effectiveness of Sorafenib Monotherapy and Selected Combination Therapy with Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
    Ho JC; Hsieh ML; Chuang PH; Hsieh VC
    Value Health Reg Issues; 2018 May; 15():120-126. PubMed ID: 29704658
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma.
    Casak SJ; Donoghue M; Fashoyin-Aje L; Jiang X; Rodriguez L; Shen YL; Xu Y; Jiang X; Liu J; Zhao H; Pierce WF; Mehta S; Goldberg KB; Theoret MR; Kluetz PG; Pazdur R; Lemery SJ
    Clin Cancer Res; 2021 Apr; 27(7):1836-1841. PubMed ID: 33139264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-utility analysis of atezolizumab combined with bevacizumab for unresectable hepatocellular carcinoma in Thailand.
    Sriphoosanaphan S; Pantumongkol W; Kulpeng W; Charonpongsuntorn C; Tanwandee T; Sukeepaisarnjaroen W; Sobhonslidsuk A; Tangkijvanich P
    PLoS One; 2024; 19(3):e0300327. PubMed ID: 38512900
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan.
    Kobayashi M; Kudo M; Izumi N; Kaneko S; Azuma M; Copher R; Meier G; Pan J; Ishii M; Ikeda S
    J Gastroenterol; 2019 Jun; 54(6):558-570. PubMed ID: 30788569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness analysis of capecitabine plus bevacizumab versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer from Chinese societal perspective.
    Zhang PF; Wen F; Zhou J; Huang JX; Zhou KX; Wu QJ; Wang XY; Zhang MX; Liao WT; Li Q
    Clin Transl Oncol; 2020 Jan; 22(1):103-110. PubMed ID: 31062173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life.
    Agirrezabal I; Brennan VK; Colaone F; Shergill S; Pereira H; Chatellier G; Vilgrain V
    Adv Ther; 2022 May; 39(5):2035-2051. PubMed ID: 35279814
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-Effectiveness Analysis of Camrelizumab Plus Rivoceranib Versus Sorafenib as a First-Line Therapy for Unresectable Hepatocellular Carcinoma in the Chinese Health Care System.
    Lang W; Deng L; Huang B; Zhong D; Zhang G; Lu M; Ouyang M
    Clin Drug Investig; 2024 Mar; 44(3):149-162. PubMed ID: 38300386
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma.
    Chiang CL; Chan SK; Lee SF; Wong IO; Choi HC
    JAMA Netw Open; 2021 Jan; 4(1):e2033761. PubMed ID: 33464318
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma.
    Soto-Perez-de-Celis E; Aguiar PN; Cordón ML; Chavarri-Guerra Y; Lopes GL
    J Natl Compr Canc Netw; 2019 Jun; 17(6):669-675. PubMed ID: 31200357
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of nivolumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma.
    Shu Y; Tang Y; Ding Y; Zhang Q
    Int Immunopharmacol; 2023 Sep; 122():110543. PubMed ID: 37406395
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.